This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm: Epididymis
CD2_BENIGN_EPIDIDYMIS_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleonly males |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D29
- Name in latin
- Neoplasma benignum epididymidis
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Epididymis
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Epididymis
- Benign neoplasm of male genital organs
- Benign neoplasm of male genital organs
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 113 | - | 113 |
| Unadjusted period prevalence (%) | 0.05 | - | 0.05 |
| Median age at first event (years) | 53.40 | - | 53.40 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 102
- Matched controls
- 1020
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D29.3
ICD-10 Finland
Benign neoplasm: Epididymis
+∞
112.2
86
*
KFD16
NOMESCO Finland
Partial excision of epididymis
146.7
22.6
23
*
2223A
ICD-9 Finland
Benign neoplasm of male genital organs, Epididymis
+∞
17.2
16
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
12.8
12
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
11.7
11
*
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
20.8
11.1
16
9
130
Kela drug reimbursment
Malignant tumour
+∞
10.6
10
*
D40.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Testis
97.8
8.6
9
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
+∞
8.4
8
*
H02AB02
ATC
dexamethasone; systemic
86.1
7.5
8
*
N43.4
ICD-10 Finland
Spermatocele
8.0
7.3
16
23
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
59
359
2.35
4.73
5.2
5.3
1.2
1.2
mmol/l
0.12
50
309
49
282
2.30
4.40
3.4
2.6
—
—
—
0
0
38
209
2.23
3.70
3.7
2.4
0.5
0.3
e6/l
0.30
27
151
50
317
2.04
3.32
3.9
3.6
—
—
—
0
0
90
729
2.15
2.76
3.3
3.6
1.8
2.0
mu/l
0.64
83
664
102
873
2.73
2.69
13.9
11.6
28.4
26.4
mg/l
0.22
84
668
105
938
2.69
2.34
17.1
14.0
90.4
86.0
umol/l
1.03
105
938
23
124
2.07
2.28
2.6
2.5
1.0
0.7
e6/l
0.19
11
63
23
133
1.92
1.88
2.4
2.3
2.7
0.8
e6/l
0.45
11
73
37
257
1.65
1.63
4.5
2.2
62.7
58.2
u/l
0.41
32
242
9
37
2.55
1.52
6.0
7.7
26.3
24.4
mmol/l
—
9
37
42
311
1.56
1.40
1.8
1.9
77.3
91.8
pmol/l
1.43
23
177
61
499
1.48
1.24
2.3
2.7
—
—
—
0
0
100
913
1.83
1.22
18.2
14.2
4.0
4.0
mmol/l
0.71
100
892
75
641
1.51
1.22
7.8
5.3
78.6
72.8
u/l
0.80
69
605
24
163
1.60
1.14
2.8
2.1
—
—
—
0
0
48
382
1.45
1.09
3.2
3.1
0.0
0.0
estimate
—
7
50
47
374
1.44
1.06
4.8
4.2
0.0
0.0
estimate
—
8
55
99
910
1.71
1.06
18.3
14.1
139.6
139.7
mmol/l
0.06
99
889
46
366
1.43
1.04
4.0
3.5
18.1
59.8
ng/l
3.19
37
271
73
633
1.43
1.01
5.2
3.5
1.9
1.8
ug/l
0.10
63
574
0
29
0.00
0.99
0.0
1.8
—
—
—
0
0
21
145
1.55
0.93
1.8
1.9
31.2
29.3
s
0.46
21
140
45
369
1.36
0.82
3.4
3.1
0.0
0.0
estimate
—
7
52
92
849
1.45
0.77
5.0
4.6
6.0
6.2
mmol/l
1.41
85
779
18
127
1.50
0.73
1.6
1.7
—
—
—
0
0
58
502
1.32
0.72
4.3
3.3
20.8
24.0
%
0.78
27
218
5
26
1.96
0.71
1.2
3.5
—
—
—
0
0
5
28
1.82
0.67
1.0
1.4
—
—
—
0
0
7
44
1.63
0.66
1.3
1.5
—
—
—
0
0
14
98
1.49
0.60
7.5
7.2
5.0
5.0
kpa
0.03
14
92
8
53
1.55
0.60
2.0
1.8
—
—
—
0
0
8
54
1.52
0.58
9.8
8.7
1.2
1.9
%
—
8
54
41
355
1.24
0.47
3.4
2.4
0.7
0.7
ug/l
0.13
28
222
5
31
1.64
0.43
1.6
1.5
—
—
—
0
0
5
31
1.64
0.43
1.8
1.1
—
—
—
0
0
86
811
1.25
0.42
14.1
10.5
78.6
81.6
ml/min/173m2
0.73
77
679
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
8
60
1.36
0.41
1.6
1.9
—
—
—
0
0
91
864
1.27
0.41
4.1
4.2
1.3
1.4
mmol/l
0.35
85
803
15
117
1.33
0.37
5.5
3.0
0.8
0.8
mmol/l
0.31
15
107
79
833
0.83
0.35
6.9
6.5
40.3
41.3
mmol/mol
0.51
74
788
7
99
0.69
0.32
1.3
1.4
—
—
—
0
0
7
55
1.29
0.30
4.9
2.0
0.0
1.7
mmol/l
—
7
37
11
87
1.29
0.25
1.3
1.6
—
—
—
0
0
34
307
1.15
0.24
3.6
3.2
—
—
—
0
0
5
41
1.23
0.22
15.0
9.1
24.2
25.1
mmol/l
—
5
36
11
89
1.26
0.22
1.4
1.8
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
1.5
—
0
5
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
11
91
1.23
0.18
2.5
2.8
6.1
5.8
kpa
0.69
11
86
13
152
0.84
0.18
1.2
1.2
0.9
1.4
u/ml
—
6
45
5
44
1.14
0.10
1.2
1.5
—
—
—
0
0
28
264
1.08
0.08
1.6
2.3
73.0
73.5
nmol/l
0.03
23
239
8
76
1.06
0.07
2.4
2.7
—
—
—
0
0
10
101
0.99
0.00
6.4
8.2
—
—
—
0
0
20
199
1.01
0.00
3.9
3.2
0.0
0.0
estimate
—
7
49
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
1066.0
—
0
5
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
7
77
0.90
0.00
1.4
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
5.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
5
53
0.94
0.00
2.8
2.0
0.9
1.5
%
—
5
53
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_EPIDIDYMIS_EXALLC – Benign neoplasm: Epididymis
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).